Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability

[1]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[2]  M. Krumbholz,et al.  B cells in MS and NMO: pathogenesis and therapy , 2014, Seminars in Immunopathology.

[3]  S. Kusunoki,et al.  Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica , 2014, Neurology.

[4]  Jacqueline A Palace,et al.  Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. , 2014, JAMA neurology.

[5]  Su-Yoen Park,et al.  Factors Associated With the Time to Next Attack in Neuromyelitis Optica: Accelerated Failure Time Models With Random Effects , 2013, PloS one.

[6]  Su-Hyun Kim,et al.  A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. , 2013, JAMA neurology.

[7]  V. Mok,et al.  Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders , 2013, Journal of the Neurological Sciences.

[8]  S. Olindo,et al.  Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  D. Furst,et al.  Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients , 2012, Annals of the rheumatic diseases.

[10]  A. Traboulsee,et al.  Treatment of Neuromyelitis Optica: Review and Recommendations. , 2012, Multiple sclerosis and related disorders.

[11]  Su-Hyun Kim,et al.  Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. , 2011, Archives of neurology.

[12]  B. Weinshenker,et al.  Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica , 2011, Neurology.

[13]  M. Krumbholz,et al.  Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab , 2011, Neurology.

[14]  B. Weinshenker,et al.  Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. , 2009, Archives of neurology.

[15]  Dennis McGonagle,et al.  Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[16]  Aaron E Miller,et al.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. , 2008, Archives of neurology.

[17]  Jun Xu,et al.  Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. , 2014, Neurology.

[18]  A. Verma.  Revised diagnostic criteria for neuromyelitis optica , 2007 .